Supplementary Table 1. Descriptive characteristics of included studies.

| **Author, Year** | **Study Design (Cohort/Trial Name, if applicable)** | **Study Country** | **Study N1** | **Mean/****Median age** | **% Male** | **Mutation(s) Assessed** | **Mutation Assessment Method(s)** | **Survival Data?** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ades, 20151 | Retrospective observational | USA | 172 | 62 | 59.9% | KRAS | MAS-PCR |  |
| Allard, 20152 | Prospective observational | France | 1659 | 65.7 | 55.8% | KRAS, BRAF, NRAS | HRM, MAS-PCR |  |
| Alonso-Espinaco 20143 | Retrospective observational | Spain | 134 | 61.7 | 62.7% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Amado, 20084 | RCT | Multicountry | 219 | 62 | 63.9% | KRAS | MAS-PCR | Y |
| Antonuzzo, 20155 | Phase IV Trial (OBELIX) | Italy | 34 | 63 | 56.4% | KRAS, BRAF | HRM, S/D |  |
| Astudillo-de la Vega, 20116 | Retrospective observational | Mexico | 807 | NR | NR | KRAS | HRM |  |
| Atreya, 20137 | Retrospective observational | USA | 62 | 57.2 | 52.4% | KRAS, BRAF, NRAS | S/D, MS |  |
| Bader, 20148 | Cross-sectional | Saudi Arabia | 30 | 55 | 57.8% | KRAS | SA |  |
| Baldus, 20109 | Retrospective observational | Germany | 100 | 65 | 56.0% | KRAS, BRAF | S/D, Pyro |  |
| Balko, 200910 | RCT technique validation | USA | 70 | NR | NR | KRAS | S/D |  |
| Berlin, 201311 | RCT | USA | 101 | 60.5 | 54.5% | KRAS | MAS-PCR | Y |
| Bibeau, 200912 | Retrospective observational | France | 64 | 60 | 67.0% | KRAS | MMA | Y |
| Bibeau, 201013 | Prospective observational | France | 560 | NR | NR | KRAS | S/D |  |
| Bokemeyer, 201114 | Retrospective analysis of RCT (OPUS) | Multicountry | 156 | 60.4 | 55.0% | KRAS, BRAF | HRM |  |
| Bruera, 201315 | Retrospective analysis of RCT | Italy | 59 | 67 | 62.7% | KRAS | MMA, S/D | Y |
| Bruera, 201416 | Retrospective observational | Italy | 37 | 69 | 59.5% | KRAS | S/D, GEM | Y |
| Bruin, 201117 | Retrospective analysis of RCT | Netherlands | 43 | 51 | 50% | KRAS, BRAF | S/D |  |
| Brulé, 201518 | Retrospective analysis of RCT (NCIC CTG CO.17) | Multicountry | 287 | 63.6 | 60.9% | KRAS, BRAF | NR | Y |
| Calero, 201519 | Retrospective observational | Spain | 90 | NR | NR | NRAS | Pyro | Y |
| Cappuzzo, 201420 | Retrospective observational | Italy | 64 | 64 | 55% | KRAS, BRAF | NR | Y |
| Cárdenas-Ramos 201421 | Retrospective observational | Mexico | 888 | NR | 60.2% | KRAS | S/D |  |
| Carneiro, 201222 | RCT | USA | 23 | 61.8 | 54.8% | KRAS, BRAF | S/D | Y |
| Carrera, 201523 | Cross-sectional | Spain | 80 | NR | NR | KRAS, NRAS | Pyro |  |
| Cejas, 200924 | Retrospective observational | Spain | 110 | NR | 70.9% | KRAS | S/D | Y |
| Chretien, 201325 | Prospective observational | France | 652 | 65.1 | 60.2% | KRAS | MMA, HRM, GEM |  |
| Ciardiello, 201426 | Retrospective observational (CAPRI-GOIM) | Italy | 182 | 62 | 55.0% | KRAS, BRAF, NRAS | NGS, S/D, MAS-PCR | Y |
| Ciardiello, 201527 | Phase IIB Trial (CONSIGN) | Italy | 686 | 62 | NR | KRAS | NR | Y |
| Conde-Herrero, 201328 | Retrospective observational | Spain | 46 | 62 | 63.0% | KRAS | NR | Y |
| Cremolini, 201529 | Retrospective observational (TRIBE) | Italy | 391 | 60 | 60.4% | KRAS, BRAF | Pyro, MS | Y |
| Cristobal, 201430 | Retrospective observational | Spain | 238 | 70 | 61.6% | KRAS | MAS-PCR |  |
| Crobach, 201531 | Retrospective observational | Netherlands | 28 | NR | 0% | KRAS | NGS, HRM, S/D |  |
| Cushman, 201532 | Retrospective analysis of RCT (CALGB 80203) | USA | 165 | 61.3 | 58.9% | KRAS | MAS-PCR |  |
| Day, 201533 | Retrospective observational | Australia | 108 | 70.5 | 40.6% | BRAF | S/D, MMA | Y |
| De Maglio, 201234 | Prospective observational | Italy | 39 | 65 | NR | KRAS, BRAF | Pyro |  |
| De Roock, 200835 | Retrospective observational (EVEREST, BOND, SALVAGE, BABEL) | Belgium | 113 | 60.7 | 61.9% | KRAS, BRAF | MAS-PCR, S/D | Y |
| De Roock, 201036 | Retrospective observational | Multicountry (Europe) | 747 | 61 | 58.1% | KRAS, BRAF, NRAS | MS, S/D, MAS-PCR | Y |
| Diaz-Rubio, 201237 | Retrospective analysis of RCT (MACRO) | Spain | 394 | 64 | 63.7% | KRAS | MAS-PCR, SA, S/D | Y |
| Di Bartolomeo, 201438 | Retrospective analysis of RCT | Italy | 23 | 77 | 56.5% | KRAS, BRAF | S/D |  |
| Di Fiore, 200739 | Prospective observational | France | 59 | NR | NR | KRAS | S/D, MMA, MAS-PCR | Y |
| Dobi, 201340 | Retrospective observational | France | 82 | 65.6 | 53.2% | KRAS | MMA | Y |
| Dono, 201241 | Retrospective observational | Italy | 213 | 77 | 56.3% | KRAS, BRAF | S/D, MAS-PCR |  |
| Dotan, 201242 | Retrospective observational | USA | 59 | 58.6 | 62.7% | KRAS | S/D |  |
| Douillard, 201043 | RCT (PRIME) | Multicountry | 550 | 61 | 60.4% | KRAS | MAS-PCR | Y |
| Douillard, 201444 | RCT (FUTURE) | Multicountry | 93 | 66 | 62.0% | KRAS | MAS-PCR | Y |
| Ducreux, 201545 | RCT (COLO-001) | France | 41 | NR | 72.0% | RAS | NR | Y |
| Elbjeirami, 201246 | Retrospective observational | Jordan | 77 | 55 | 55% | KRAS | MAS-PCR, S/D, SA |  |
| Erdamar 201147 | Retrospective observational | Turkey | 202 | 60.6 | 60.9% | KRAS, BRAF | MAS-PCR |  |
| Fadhil, 201248 | Retrospective observational | United Kingdom | 50 | NR | NR | KRAS, BRAF | HRM, S/D |  |
| Fanetti, 201349 | Retrospective observational | Italy | 55 | NR | NR | KRAS | S/D |  |
| Fanta, 201250 | Retrospective observational | USA | 120 | NR | NR | KRAS, BRAF | MAS-PCR |  |
| Feigelson, 201451 | Retrospective observational (CERGEN) | USA | 839 | 66.4 | 50.7% | KRAS | S/D | Y |
| Feng, 201652 | Retrospective observational | China | 198 | 54.6 | 67.7% | RAS, BRAF | Pyro |  |
| Fiala, 201553 | Retrospective observational (CORRECT) | Czech Republic | 358 | 63.0 | 62.0% | KRAS | S/D, MAS-PCR, SA | Y |
| Folprecht, 201054 | Phase II RCT (CELIM) | Germany, Austria  | 50 | 65.1 | 64.3% | KRAS, BRAF | S/D, MAS-PCR, GEM |  |
| Fornaro, 201155 | Retrospective observational | Italy | 52 | 73 | 63.0% | KRAS, BRAF | Pyro | Y |
| Francisco, 201056 | Cross-sectional | USA | 58 | NR | NR | KRAS | Other |  |
| Freeman, 200857 | Retrospective analysis of RCT | USA | 62 | 62 | 59.7% | KRAS, BRAF | S/D | Y |
| Gajate, 201258 | Retrospective observational | Spain | 110 | 67.7 | 53.6% | KRAS | MAS-PCR | Y |
| Gao, 201159 | Retrospective observational | China | 59 | 57 | 64.4% | KRAS, BRAF | S/D | Y |
| Garawin, 201560 | Prospective observational | Multicountry (Asia) | 750 | NR | NR | KRAS, BRAF, NRAS | HRM |  |
| Garcia Foncillas, 201261 | Retrospective observational | Spain | 669 | NR | NR | KRAS | MAS-PCR, HRM |  |
| Garcia-Albeniz, 201162 | Prospective observational | Spain | 74 | 63 | 63.0% | KRAS, BRAF | S/D | Y |
| Garrido-Laguna, 201263 | Retrospective observational | USA | 238 | NR | 54.0% | KRAS, BRAF | S/D, Pyro | Y |
| Garufi, 201064 | Phase II Trial (POCHER) | Italy | 37 | 61 | 63.0% | KRAS | S/D |  |
| Ghidini, 201665 | Retrospective observational | Italy | 75 | 65.4 | 36.0% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Gil Ferreira, 201466 | Retrospective observational | Brazil | 7797 | 60 | 51.9% | KRAS | S/D |  |
| Gillern, 201067 | Retrospective observational | USA | 23 | 53 | 52.0% | KRAS | Other |  |
| Goldstein, 201468 | Retrospective observational | Multicountry | 47 | 67 | 42.0% | BRAF | MAS-PCR | Y |
| Goncalves, 200869 | Retrospective observational | France | 32 | 58 | 50.0% | KRAS | S/D | Y |
| Graziano, 201070 | Retrospective observational | Italy | 134 | 65 | 54.0% | KRAS, BRAF | Pyro | Y |
| Guedes, 201371 | Retrospective observational | Portugal | 201 | NR | NR | KRAS, BRAF | HRM, S/D |  |
| Gumus, 201572 | Prospective observational (TURKRAS) | Turkey | 2458 | NR | 61.2% | KRAS | MMA |  |
| Harbison, 201373 | RCT (CRYSTAL) | Multicountry | 228 | 63.4 | 64.9% | KRAS | MAS-PCR | Y |
| Harlé, 201574 | Retrospective observational | France | 177 | 69.2 | 57.6% | KRAS, NRAS | Pyro |  |
| Hecht, 200975 | RCT (PAACE) | USA | 425 | 60.6 | 58.9% | KRAS | MAS-PCR | Y |
| Heinemann, 201476 | Phase III RCT (FIRE-3) | Germany, Austria | 592 | 64 | 69.3% | RAS | Pyro | Y |
| Heqedus, 201177 | Prospective observational | Hungary | 35 | NR | NR | KRAS | S/D | Y |
| Hikosaka, 201478 | Prospective observational | Japan | 217 | NR | NR | KRAS2 | Pyro | Y |
| Hong, 201379 | Prospective observational | South Korea | 80 | 55 | 65.0% | KRAS2 | S/D | Y |
| Hsieh, 201280 | Prospective observational | Taiwan | 112 | NR | 71.4% | KRAS2 | S/D | Y |
| Huang, 201181 | Prospective observational | Taiwan | 98 | 58 | 52.0% | KRAS2 | S/D | Y |
| Huang, 201382 | Retrospective observational | Taiwan | 205 | 61.0 | 58.5% | KRAS | S/D | Y |
| Hurtwitz, 200983 | Phase III RCT | USA | 101 | 58 | 53.5% | KRAS | S/D | Y |
| Ilie, 201484 | Retrospective observational | France | 489 | 63.5 | 68.0% | KRAS, BRAF | Pyro, S/D |  |
| Inno, 201185 | Retrospective observational | Italy | 73 | 58 | 58.9% | KRAS, BRAF | S/D | Y |
| Isella, 201386 | Prospective observational | Italy | 64 | 66.4 | 81.3% | KRAS, BRAF, NRAS | S/D, MAS-PCR |  |
| Italiano, 201087 | Retrospective observational | France | 61 | 65 | 67.0% | KRAS, BRAF | S/D, Other |  |
| Ito, 201388 | Prospective observational | Japan | 67 | 65 | 67.7% | BRAF | S/D | Y |
| Iwamoto, 201489 | Phase II RCT (FLIER) | Japan | 60 | 62 | 65.0% | BRAF | S/D |  |
| Jakovljevic, 201290 | Retrospective observational | Serbia | 190 | 60 | 63.7% | KRAS, BRAF | MAS-PCR, SA, HRM |  |
| Jeffers, 201391 | Phase III RCT (CORRECT) | Germany | 742 | NR | NR | KRAS, BRAF | Other |  |
| Kaczirek, 201592 | Retrospective analysis of RCT (CECOG/CORE 1.2.002) | Multicountry | 148 | 66 | 57.0% | RAS, BRAF, NRAS | MAS-PCR, S/D, Pyro | Y |
| Kaneko, 201493 | Prospective observational | Japan | 90 | 62.9 | 63.3% | KRAS | S/D, MAS-PCR |  |
| Karagkounis, 201394 | Prospective observational | USA | 202 | 61 | 66.0% | KRAS, BRAF | S/D | Y |
| Kemeny, 201495 | Retrospective observational | USA | 169 | 56 | 58.6% | KRAS, BRAF, NRAS | MS | Y |
| Kim, 201296 | Retrospective observational | South Korea | 143 | 59 | 53.8% | KRAS | S/D |  |
| Kim, 201297 | Retrospective observational | South Korea | 49 | NR | NR | KRAS | Pyro |  |
| Kim, 201698 | Retrospective observational | South Korea | 82 | 55.5 | 54.0% | KRAS | MAS-PCR | Y |
| Knijn, 201199 | Retrospective observational (CAIRO2) | Netherlands | 305 | 65 | 62.6% | KRAS | S/D |  |
| Ko, 2011100 | Retrospective observational | Canada | 70 | 70 | 70.0% | KRAS, BRAF | GEM, MAS-PCR |  |
| Kodaz, 2015101 | Retrospective observational | Turkey | 189 | 61 | 64.6% | KRAS | Pyro |  |
| Kohne, 2011102 | Phase II Trial  | Multicountry (Europe) | 145 | 64 | 68.0% | KRAS | MAS-PCR | Y |
| Kohnoe, 2011103 | Retrospective observational | Japan | 32 | NR | NR | KRAS | S/D |  |
| Koike, 2014104 | Retrospective observational | Japan | 49 | NR | NR | KRAS | NR | Y |
| Korphaisarn, 2015105 | Retrospective observational | Thailand | 29 | 63 | 50.2% | BRAF | MAS-PCR |  |
| Kosmidou, 2014106 | Prospective observational | Greece | 26 | NR | NR | KRAS, BRAF | S/D, Pyro |  |
| Langer, 2008107 | Phase III RCT (EPIC) | USA | 300 | NR | NR | KRAS | S/D | Y |
| László, 2010108 | Retrospective observational | Hungary | 26 | NR | 56.8% | KRAS, BRAF | S/D |  |
| Lau, 2015109 | Prospective observational | Hong Kong | 67 | 62.7 | 65.7% | KRAS, NRAS | S/D |  |
| Laurent-Puig, 2009110 | Retrospective observational | France | 169 | NR | NR | KRAS, BRAF | MAS-PCR | Y |
| Li, 2010111 | Retrospective observational | China | 90 | 53 | 65.6% | KRAS | S/D | Y |
| Li, 2011112 | Retrospective observational | China | 74 | 53 | 58.1% | KRAS | MAS-PCR, MMA, S/D | Y |
| Li, 2015113 | Prospective observational | China | 87 | 63 | 65.5% | KRAS | Other | Y |
| Liao, 2010114 | Retrospective observational | China | 61 | NR | 71.0% | KRAS, BRAF | Pyro | Y |
| Licar, 2010115 | Retrospective observational | Slovenia | 268 | NR | NR | KRAS, BRAF | MAS-PCR |  |
| Lin, 2011116 | Retrospective observational | Taiwan | 42 | 57 | 45.2% | KRAS, BRAF | S/D | Y |
| Lin, 2014117 | Prospective observational | China | 154 | NR | 57.8% | KRAS | Pyro | Y |
| Liou, 2011118 | Prospective observational | Taiwan | 35 | NR | 54.5% | KRAS, BRAF | S/D | Y |
| Losi, 2007119 | Retrospective observational | Italy, Switzerland | 71 | 63.3 | 54.9% | KRAS | GEM |  |
| Loupakis, 2009120 | Prospective observational | Italy | 138 | 61 | 55.0% | KRAS, BRAF | S/D | Y |
| Loupakis, 2009121 | Retrospective observational | Italy | 88 | 62 | 59.0% | BRAF | Pyro | Y |
| Loupakis, 2015122 | Prospective observational (PROVETTA) | Italy | 200 | NR | 63.0% | KRAS | NR | Y |
| Lurje, 2009123 | Retrospective observational (IMC 0144) | USA | 130 | NR | 49.2% | KRAS | GEM, S/D | Y |
| Ma, 2012124 | Retrospective observational | China | 183 | 58 | NR | KRAS, BRAF | S/D |  |
| Ma, 2013125 | RCT | China | 44 | 56.5 | 63.0% | KRAS | S/D |  |
| Ma, 2015126 | Retrospective observational | China | 183 | 58 | 56.8% | KRAS, BRAF, NRAS | S/D | Y |
| MacEdo, 2012127 | Cross-sectional | Brazil | 63 | NR | NR | KRAS | Pyro |  |
| Maesto, 2007128 | Prospective observational | Spain | 77 | 69.6 | 52.1% | BRAF | HRM |  |
| Magge, 2013129 | Retrospective observational | USA | 70 | NR | NR | KRAS | Other | Y |
| Mariani, 2010130 | Retrospective observational | France | 38 | 62.5 | 50.0% | KRAS, BRAF | MMA, MAS-PCR, S/D |  |
| Martin, 2013131 | Retrospective observational | Greece, Switzerland, Italy, Belgium | 170 | 62 | 60.0% | KRAS2 | NR |  |
| Mekenkamp, 2012132 | Retrospective analysis of RCT (CAIRO2) | Netherlands | 34 | 58.6 | 59.0% | KRAS | S/D |  |
| Michl, 2015133 | Retrospective observational | Germany | 65 | NR | 58.5% | KRAS, BRAF | Pyro |  |
| Miglio, 2013134 | Retrospective observational | Italy | 45 | 66.4 | 62.2% | KRAS | MAS-PCR |  |
| Miranda, 2013135 | Retrospective observational | Italy | 34 | NR | NR | KRAS, BRAF | GEM |  |
| Mitchell, 2011136 | RCT | USA | 87 | 62.5 | 62.1% | KRAS | MAS-PCR | Y |
| Modest, 2011137 | Retrospective observational (FIRE-3; AIO KRK-0104) | Germany | 273 | 64 | 68.3% | KRAS | Pyro |  |
| Modest, 2012138 | Retrospective analysis of RCT (AIO KRK-0104) | Germany | 146 | 63 | 71.9% | KRAS, BRAF | Pyro | Y |
| Moehler, 2015139 | Retrospective observational | Germany | 71 | 63 | 70.0% | KRAS | HRM |  |
| Molinari, 2009140 | Prospective observational | Switzerland | 37 | 67 | 63.0% | KRAS, BRAF | S/D |  |
| Molinari, 2011141 | Retrospective observational | Italy, Switzerland | 111 | NR | 59.0% | KRAS, BRAF | S/D, MS, MAS-PCR |  |
| Montomoli, 2012142 | Retrospective observational | Denmark | 106 | 61 | 64.0% | KRAS | MAS-PCR | Y |
| Moosmann, 2011143 | RCT (AIO KRK-0104) | Germany | 73 | 63 | 70.8% | KRAS | Pyro | Y |
| Morris, 2014144 | Retrospective observational | USA | 473 | 54.6 | 57.0% | KRAS, BRAF, NRAS | NGS | Y |
| Mostert, 2013145 | Prospective observational | Netherlands | 43 | 65 | 65.0% | KRAS, BRAF | S/D, MAS-PCR |  |
| Murata, 2013146 | Prospective observational | Japan | 32 | NR | 61.9% | KRAS, BRAF | Pyro |  |
| Muro, 2009147 | Phase II Trial | Japan | 24 | 59 | 65.0% | KRAS | MAS-PCR | Y |
| Nash, 2010148 | Retrospective observational | USA | 188 | 63 | 61.7% | KRAS | GEM |  |
| Nash, 2010149 | Retrospective observational | USA | 147 | 67 | 51.3% | KRAS | GEM |  |
| NCT00835185150 | Phase II Trial  | Belgium, Spain | 25 | 63.3 | 56.8% | KRAS | NR |  |
| Netter, 2015151 | Retrospective observational | France | 67 | 62.4 | 51.0% | KRAS, BRAF | MAS-PCR | Y |
| Neumann, 2009152 | Prospective observational | Germany | 1018 | 63.8 | 62.4% | KRAS | S/D, Pyro |  |
| Neumann, 2013153 | Retrospective observational | Germany | 97 | NR | NR | KRAS, BRAF | Pyro |  |
| Ng, 2013154 | Phase II RCT | USA | 160 | 61.3 | 52.3% | KRAS, BRAF | S/D | Y |
| Ocvirk, 2010155 | Phase II RCT (CECOG/CORE 1.2.001) | Multicountry | 117 | 62.8 | 58.3% | KRAS | MAS-PCR | Y |
| Oliveria, 2007156 | Cross-sectional | Portugal, France, Spain | 40 | NR | NR | KRAS, BRAF | GEM, S/D |  |
| Ortiz, 2015157 | Prospective observational | Spain | 324 | NR | NR | KRAS, BRAF, NRAS | MS |  |
| Osumi, 2015158 | Retrospective observational | Japan | 98 | 64.5 | 54.1% | KRAS | MMA, S/D | Y |
| Osumi, 2016159 | Prospective observational | Japan | 132 | 63 | 53.0% | RAS, KRAS, BRAF, NRAS | MMA | Y |
| Paez 2010160 | Prospective observational | Spain | 104 | 64 | 64.0% | KRAS | S/D | Y |
| Pai, 2012161 | Retrospective observational | USA | 34 | NR | 53.0% | KRAS, BRAF | MAS-PCR, S/D, HRM |  |
| Paliogiannis, 2014162 | Prospective observational | Italy | 729 | NR | 61.0% | KRAS | S/D |  |
| Palmirotta, 2012163 | Prospective observational | Italy | 230 | 66.2 | 59.6% | KRAS | S/D |  |
| Park, 2011164 | Prospective observational | South Korea | 69 | 54 | 62.7% | KRAS, BRAF | S/D | Y |
| Peeters, 2009165 | RCT | Multicountry | 363 | 62 | 63.0% | KRAS | MAS-PCR |  |
| Peeters, 2010166 | RCT | Multicountry | 542 | 64 | 62.6% | KRAS | MAS-PCR | Y |
| Peeters, 2013167 | Retrospective analysis of RCT | Multicountry | 1096 | NR | NR | KRAS | MAS-PCR |  |
| Peeters, 2014168 | RCT | Multicountry | 542 | 64 | 62.5% | KRAS | MAS-PCR | Y |
| Pekin, 2013169 | Retrospective observational | France | 95 | 62 | 56.8% | KRAS | MMA |  |
| Pereira, 2014170 | Retrospective observational | USA | 494 | 56 | 59.0% | KRAS | S/D, MS | Y |
| Perez-Ruiz, 2012171 | Retrospective observational | Spain | 120 | 65 | 61.7% | KRAS | MAS-PCR, SA | Y |
| Perrone, 2009172 | Retrospective observational | Italy | 29 | 45 | 62.5% | KRAS, BRAF | S/D | Y |
| Phua, 2015173 | Retrospective observational | Singapore | 45 | 64.5 | 64.4% | KRAS, BRAF | S/D |  |
| Pichler, 2014174 | Retrospective observational | Austria | 80 | 60 | 67.5% | KRAS2 | Pyro | Y |
| Pietrantonio, 2014175 | Phase II Trial | Italy | 31 | 60 | 36.0% | KRAS, BRAF, NRAS | S/D |  |
| Pietrantonio, 2015176 | Retrospective observational | Italy | 74 | NR | NR | KRAS, NRAS | NGS |  |
| Pinto, 2011177 | Prospective observational | Portugal | 372 | NR | NR | KRAS | S/D, MAS-PCR, HRM, MMA |  |
| Piton, 2015178 | Prospective observational | France | 6803 | NR | NR | KRAS, NRAS | S/D, NGS, SA, HRM, MAS-PCR, MMA, Pyro, MS, Other |  |
| Price, 2011179 | Phase III RCT (MAX) | Australia | 314 | 69 | 63.0% | KRAS, BRAF | HRM, S/D | Y |
| Price, 2014180 | Phase III RCT (ASPECCT) | Multicountry | 500 | 60.5 | 64.0% | KRAS2 | MAS-PCR | Y |
| Price, 2014181 | Cross-sectional | Australia | 2877 | 75.8 | 57.7% | KRAS | NR |  |
| Price, 2016182 | Cross-sectional | Australia | 227 | 71.5 | 59.5% | KRAS, BRAF | NR | Y |
| Primrose, 2014183 | Phase III RCT | UK | 128 | 64 | 63.0% | KRAS | Pyro | Y |
| Ribeiro, 2013184 | Retrospective observational | Brazil | 65 | NR | 43.1% | KRAS | NR | Y |
| Rojo, 2012185 | Retrospective observational | Spain | 1238 | NR | NR | KRAS, BRAF | MAS-PCR |  |
| Rose, 2012186 | Retrospective observational | USA | 110 | 55.4 | 47.3% | KRAS | S/D | Y |
| Rosenthal, 2015187 | Retrospective observational | USA | 65 | 55.7 | 57.0% | KRAS | MAS-PCR | Y |
| Rossi, 2012188 | Retrospective observational | Italy | 108 | 55 | 63.0% | KRAS | S/D |  |
| Russo, 2014189 | Retrospective observational | USA | 222 | 56 | 58.0% | KRAS, BRAF, NRAS | MMA | Y |
| Ruzzo, 2012190 | Retrospective observational | Italy | 172 | NR | NR | KRAS | Pyro |  |
| Saito, 2014191 | Prospective observational | Japan | 109 | 63.5 | 57.8% | KRAS | MAS-PCR, S/D |  |
| Saltz, 2012192 | RCT | USA | 117 | 61.2 | 56.5% | KRAS | S/D | Y |
| Santini, 2008193 | Retrospective observational | Italy | 99 | 71 | 50.5% | KRAS | S/D |  |
| Saridaki, 2010194 | Prospective observational | Greece | 144 | 64 | 57.0% | BRAF | MAS-PCR | Y |
| Saridaki, 2013195 | Prospective observational | Greece | 504 | 64 | 59.0% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Saridaki, 2014196 | Retrospective observational | Belgium, France | 512 | 61 | 56.8% | KRAS, BRAF | MS, S/D, MAS-PCR |  |
| Sartore-Bianchi, 2009197 | Retrospective observational | Italy, Switzerland | 110 | 64 | 64.6% | KRAS | S/D | Y |
| Sartore-Bianchi, 2009198 | Retrospective observational | Italy, Switzerland | 132 | 63.5 | 65.2% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Scartozzi, 2012199 | Retrospective observational | Italy | 168 | NR | 66.0% | KRAS | S/D | Y |
| Schimanski, 2011200 | Prospective observational | Germany | 22 | NR | NR | KRAS | GEM |  |
| Schirripa, 2015201 | Prospective observational | Italy | 786 | 64 | 59.0% | KRAS, BRAF, NRAS | Pyro, S/D | Y |
| Schwartzberg, 2014202 | Phase II RCT (PEAK) | Multicountry | 112 | 61 | 67.0% | KRAS, NRAS | MAS-PCR, S/D | Y |
| Schweiger, 2014203 | Prospective observational | Austria | 39 | 64 | 51.3% | KRAS, BRAF | GEM |  |
| Sebio, 2013204 | Prospective observational | Spain | 79 | 66 | 64.0% | BRAF | MMA, MAS-PCR, NGS |  |
| Selcukbiricik, 2013205 | Retrospective observational | Turkey | 172 | 60.5 | 37.2% | KRAS, BRAF | MAS-PCR, HRM | Y |
| Shen, 2011206 | Prospective observational | China | 15 | 61 | NR | KRAS | Pyro | Y |
| Shen, 2013207 | Prospective observational | China | 55 | NR | NR | KRAS, BRAF, NRAS | S/D |  |
| Shimomura, 2013208 | Prospective observational | Japan | 64 | 62 | 65.6% | KRAS, BRAF | S/D |  |
| Shoji, 2014209 | Prospective observational | Japan | 108 | 63 | 60.2% | KRAS, BRAF | S/D |  |
| Shulman, 2012210 | Prospective observational | Israel | 333 | NR | NR | BRAF | S/D, MAS-PCR |  |
| Shulman, 2013211 | Prospective observational | Israel | 397 | NR | NR | KRAS | S/D, MAS-PCR |  |
| Siyar Ekinci, 2015212 | Retrospective observational | Turkey | 31 | 63 | 48.4% | KRAS | Pyro | Y |
| Skougaard, 2014213 | Phase II Trial | Denmark | 61 | 62 | 60.7% | KRAS | MAS-PCR |  |
| Smith, 2014214 | Prospective observational | USA | 51 | 62 | NR | KRAS, BRAF, NRAS | NGS |  |
| Smits, 2011215 | Retrospective observational | Netherlands | 734 | 67.9 | 55.6% | KRAS | S/D, GEM |  |
| Soeda, 2014216 | Phase II RCT | Japan | 43 | 67 | 62.8% | KRAS, BRAF, NRAS | S/D | Y |
| Soeda, 2014217 | Retrospective observational | Japan | 194 | 65 | 57.2% | KRAS, BRAF, NRAS | Other | Y |
| Sohal, 2015218 | Prospective observational | USA | 44 | 60 | 49.0% | KRAS | NGS |  |
| Sood, 2012219 | Prospective observational | USA | 76 | 59 | 29.0% | KRAS, BRAF | Pyro | Y |
| Sorbye, 2015220 | Prospective observational | Multicountry (Scandinavia) | 446 | 63 | 50.0% | KRAS, BRAF | Pyro | Y |
| Souglakos, 2009221 | Prospective observational | Multicountry | 168 | 59 | 52.0% | KRAS, BRAF | MS, S/D | Y |
| Spindler, 2011222 | Retrospective observational | Denmark | 94 | 62 | 54.0% | BRAF | MAS-PCR | Y |
| Spindler, 2012223 | Retrospective observational | Denmark | 98 | 62 | 56.0% | KRAS | MAS-PCR | Y |
| Spindler, 2012224 | RCT (Nordic ACT) | Denmark | 110 | NR | NR | KRAS, BRAF | MAS-PCR |  |
| Stahler, 2016225 | RCT (FIRE-1) | Germany | 108 | 63 | 66.4% | KRAS, NRAS | Pyro |  |
| Stintzing, 2012226 | RCT | Germany, Austria | 50 | 65 | 64.0% | KRAS2 | NR | Y |
| Stremitzer, 2012227 | Prospective observational | Austria | 60 | 60.3 | 60.0% | KRAS | S/D | Y |
| Suenaga, 2010228 | Prospective observational | Japan | 85 | NR | NR | KRAS | S/D |  |
| Tabernero, 2013229 | RCT (RESPECT) | Multicountry | 94 | 60.3 | 62.4% | KRAS, BRAF | MMA | Y |
| Tabernero, 2015230 | Retrospective observational (CORRECT) | Multicountry | 166 | 61 | 61.0% | KRAS | Other |  |
| Takahashi, 2014231 | Prospective observational | Japan | 103 | 62 | 68.0% | KRAS2 | NR | Y |
| Takahashi, 2014232 | Retrospective observational | Japan | 337 | NR | NR | KRAS, BRAF, NRAS | S/D | Y |
| Tejpar, 2010233 | Retrospective observational | Multicountry (Europe) | 790 | NR | NR | KRAS, BRAF, NRAS | MS | Y |
| Teng, 2012234 | Retrospective observational | Taiwan | 292 | 61 | 60.6% | KRAS, BRAF | S/D | Y |
| Teufel, 2015235 | Phase III RCT (CORRECT) | China | 143 | NR | NR | KRAS, BRAF, NRAS | Other |  |
| Tie, 2009236 | Cross-sectional | Australia | 129 | 69.5 | 49.0% | KRAS, BRAF | MAS-PCR | Y |
| Tie, 2011237 | Retrospective observational | Australia | 144 | 77.6 | 49.7% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Tie, 2011238 | Retrospective observational | Australia | 161 | NR | 62.8% | KRAS, BRAF, NRAS | S/D, HRM |  |
| Tol, 2010239 | Phase III RCT (CAIRO2) | Netherlands | 518 | NR | 58.0% | KRAS, BRAF | S/D, MAS-PCR | Y |
| Tommasi, 2011240 | Retrospective observational | Italy | 75 | 64 | 58.7% | KRAS, BRAF | S/D |  |
| Tougeron, 2013241 | Prospective observational | France | 168 | 64.3 | 62.5% | KRAS2 | S/D | Y |
| Tran, 2011242 | Retrospective observational | Multicountry | 524 | 66 | 55.2% | BRAF | MAS-PCR | Y |
| Tsimberdou, 2012243 | Phase I Trial | USA | 76 | 62 | 55.3% | KRAS2 | NR | Y |
| Tural 2013244 | Retrospective observational | Turkey | 105 | NR | NR | KRAS2 | NR | Y |
| Tural, 2014245 | Retrospective observational | Turkey | 41 | 58 | 56.0% | BRAF | MAS-PCR | Y |
| Tviet, 2012246 | Phase III RCT (NORDIC-VII) | Multicountry (Scandinavia) | 155 | 61 | 55.0% | KRAS, BRAF | MAS-PCR | Y |
| Ulivi, 2012247 | Retrospective observational | Italy | 39 | 61 | 58.2% | KRAS, BRAF | S/D | Y |
| Umeda, 2013248 | Prospective observational | Japan | 100 | 60 | 55.0% | KRAS, BRAF | S/D, GEM |  |
| Unger, 2013249 | Prospective observational | Germany | 40 | 65.5 | 65.0% | KRAS | NR |  |
| Usakova, 2013250 | Retrospective observational | Slovak Republic | 56 | 55.7 | 58.6% | KRAS, BRAF | MMA |  |
| Usakova, 2013251 | Prospective observational | Slovak Republic | 21 | 59 | 47.6% | KRAS, BRAF | NR | Y |
| Vakiani, 2012252 | Retrospective observational | USA | 613 | 62 | 54.7% | KRAS, BRAF, NRAS | MMA, S/D |  |
| Van Cutsem, 2011253 | Phase III RCT | Multicountry | 533 | 63 | 59.5% | KRAS, BRAF | HRM | Y |
| Van den Broek, 2015254 | Retrospective analysis of RCT (CAIRO; CAIRO2) | Netherlands | 203 | 63 | 57.1% | NRAS | NGS |  |
| Vatandoust, 2014255 | Cross-sectional | Australia | 2862 | NR | NR | KRAS | NR |  |
| Vauthey, 2013256 | Retrospective observational | USA | 193 | NR | NR | KRAS, BRAF, NRAS | MS |  |
| Veldore, 2014257 | Retrospective observational | India | 299 | 55.9 | 65.2% | KRAS | MAS-PCR |  |
| Vermaat, 2012258 | Prospective observational | Netherlands | 21 | 60.7 | 52.4% | KRAS, BRAF, NRAS | NGS |  |
| Victoria, 2013259 | Cross-sectional | Spain | 45 | NR | NR | KRAS, BRAF | NR |  |
| Voutsina, 2013260 | Retrospective observational | Greece | 83 | NR | 51.8% | KRAS, BRAF | S/D, MAS-PCR, MMA | Y |
| Watanabe, 2011261 | Retrospective observational | Japan | 43 | 65 | 69.8% | KRAS | S/D |  |
| Weeraratne, 2011262 | Retrospective analysis of RCT | Multicountry | 1124 | NR | NR | KRAS | MAS-PCR |  |
| Weickhardt, 2012263 | Phase II RCT (DUX) | Australia | 50 | 63 | 60.0% | KRAS, BRAF | HRM | Y |
| Wong, 2011264 | Phase II RCT | USA | 29 | 56 | 53.0% | KRAS, BRAF | MAS-PCR | Y |
| Xu, 2014265 | Retrospective observational | China | 416 | 56 | 52.4% | KRAS | S/D, Other | Y |
| Yaeger, 2014266 | Prospective observational | USA | 515 | 64 | 52.0% | BRAF | S/D, MS | Y |
| Yaeger, 2015267 | Retrospective observational | USA | 1095 | 58 | 53.7% | KRAS, NRAS | S/D, MS |  |
| Yang, 2014268 | Retrospective observational | Taiwan | 95 | NR | 66.3% | KRAS | S/D | Y |
| Ye, 2012269 | Phase IV RCT | China | 57 | NR | NR | KRAS, BRAF2 | NR | Y |
| Yen, 2010270 | Retrospective observational | Taiwan | 95 | 66 | 57.9% | KRAS | S/D | Y |
| Yokota, 2011271 | Retrospective observational | Japan | 229 | 62 | 58.5% | KRAS, BRAF2 | MAS-PCR | Y |
| Zazo, 2012272 | Cross-sectional | Spain | 1238 | NR | NR | KRAS, BRAF | MAS-PCR |  |
| Zhang, 2010273 | Retrospective analysis of RCT (IMCL-0144) | Muticountry | 130 | 60 | 49.0% | KRAS | S/D, GEM | Y |
| Zimmitti, 2015274 | Prospective observational | USA | 184 | 58 | 58.0% | KRAS, NRAS | MS |  |
| Zlobec, 2010275 | Prospective observational | Switzerland | 45 | 63.2 | 62.2% | KRAS, BRAF | S/D |  |

1Number of patients with available mutation testing results

2Mutation prevalence data not available in this article

Abbreviations: GEM, Gel Electrophoresis Methods; HRM, High Resolution Melting; MAS-PCR, Mutant allele specific PCR; MMA, Multiplex Mutation Assay; MS, Mass Spectrometry; NGS, Next Generation Sequencing; NR, not reported; Pyro, Pyrosequencing; RCT, randomized controlled trial; SA, Strip Assay; S/D, Sanger/Direct Sequencing (PCR);

1. Ades S, Kumar S, Alam M, et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. *J Thromb Haemost.* 2015;13(6):998-1003.

2. Allard MA, Saffroy R, de la Maisonneuve PB, et al. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? *Target Oncol.* 2015;10(3):415-421.

3. Alonso-Espinaco V, Cuatrecasas M, Alonso V, et al. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. *Eur J Cancer.* 2014;50(11):1973-1981.

4. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol.* 2008;26(10):1626-1634.

5. Antonuzzo L, Giommoni E, Pastorelli D, et al. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. *World J Gastroenterol.* 2015;21(23):7281-7288.

6. Astudillo-de la Vega H, PRomero-Garcia P, Silva JA. Identification of KRas mutational polymorphism by molecular analysis using high-resolution melting system in a large MCRC mexican sample. *Proffered Papers.* 2011:S124-125.

7. Atreya CE, Sangale Z, Xu N, et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. *Cancer Med.* 2013;2(4):496-506.

8. Bader T, Ismail A. Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. *Alexandria Journal of Medicine.* 2014;50(3):203-209.

9. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin Cancer Res.* 2010;16(3):790-799.

10. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. *BMC Cancer.* 2009;9:145.

11. Berlin J, Bendell JC, Hart LL, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Clin Cancer Res.* 2013;19(1):258-267.

12. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. *J Clin Oncol.* 2009;27(7):1122-1129.

13. Bibeau F, Frugier H, Crapez E, Lamy P, Ychou M, Boissiere-Michot F. KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results. *J Clin Oncol.* 2010;32(Suppl 3).

14. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol.* 2011;22(7):1535-1546.

15. Bruera G, Cannita K, Di Giacomo D, et al. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). *BMC Med.* 2013;11:59.

16. Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. *Int J Oncol.* 2014;44(6):1820-1830.

17. Bruin SC, He Y, Mikolajewska-Hanclich I, et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. *British journal of cancer.* 2011;105(2):281-287.

18. Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. *Eur J Cancer.* 2015;51(11):1405-1414.

19. Calero BM, Llanos M, Alvarez BA, Hernandez San Gil R, Salido E, al. e. Analysis of KRAS and NRAS mutations in 126 patients with KRAS exon 2 wild type for metastatic colorectal cancer (mCRC) in a single institution. *J Clin Oncol.* 2015;33(Suppl):Abstr e14589.

20. Cappuzzo F, Sacconi A, Landi L, et al. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. *Clin Colorectal Cancer.* 2014;13(1):37-45 e34.

21. Cardenas-Ramos SG, Alcazar-Gonzalez G, Reyes-Cortes LM, et al. The Frequency and Type of K-RAS Mutations in Mexican Patients with Colorectal Cancer: A National Study. *Am J Clin Oncol.* 2014;00(00):1-3.

22. Carneiro BA, Ramanathan RK, Fakih MG, et al. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. *Clin Colorectal Cancer.* 2012;11(1):53-59.

23. Carrera R, Blazquez C, Casalots A, et al. KRAS and NRAS mutations in metastatic colorectal cancer (CRCm) analyzed by pyrosequencing: PS-10-033. *Virchows Arch.* 2015;467(Suppl1):S166.

24. Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. *PLoS One.* 2009;4(12):e8199.

25. Chretien AS, Harle A, Meyer-Lefebvre M, et al. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. *Cancer Med.* 2013;2(1):11-20.

26. Ciardiello F, Normanno N, Maiello E, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. *Ann Oncol.* 2014;25(9):1756-1761.

27. Ciardiello F, Falcone A, Cascinu S, et al. Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. *Abstracts.* 2015:S380-S381.

28. Conde-Herrero V, Gonzalez-Astorga B, Gonzalez-Vicente A, et al. Outcomes According to Kras Mutational Status in Treatment with Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: P-0248. *Annals of Oncology.* 2013;24(suppl 4):iv106-iv106.

29. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *The Lancet Oncology.* 2015;16(13):1306-1315.

30. Cristobal I, Rincon R, Manso R, et al. Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research.* 2014;21(2):347-356.

31. Crobach S, Ruano D, van Eijk R, et al. Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue. *J Mol Diagn.* 2015;17(2):193-200.

32. Cushman SM, Jiang C, Hatch AJ, et al. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). *Clin Cancer Res.* 2015;21(5):1078-1086.

33. Day F, Muranyi A, Singh S, et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. *Target Oncol.* 2015;10(1):99-109.

34. De Maglio G, Lutrino ES, S. C, et al. Molecular Profiling of Brain Metastases from Colorectal Cancer. *Annual Meetings Abstracts.* 2012;92:429A-430A.

35. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. *Ann Oncol.* 2008;19(3):508-515.

36. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol.* 2010;11(8):753-762.

37. Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. *PLoS One.* 2012;7(10):e47345.

38. Di Bartolomeo M, Pietrantonio F, Perrone F, et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. *Target Oncol.* 2014;9(2):155-162.

39. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. *British journal of cancer.* 2007;96(8):1166-1169.

40. Dobi E, Monnien F, Kim S, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. *Clin Colorectal Cancer.* 2013;12(1):28-36.

41. Dono M, Massucco C, Chiara S, et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. *Mol Med.* 2013;18:1519-1526.

42. Dotan E, Meropol NJ, Zhu F, et al. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. *British journal of cancer.* 2012;106(4):748-755.

43. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol.* 2010;28(31):4697-4705.

44. Douillard JY, Zemelka T, Fountzilas G, et al. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. *Clin Colorectal Cancer.* 2014;13(1):14-26 e11.

45. Ducreux M, Bennouna J, Adenis A, et al. Efficacy and safety of nab-paclitaxel (nab-P) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): The phase II COLO-001 trial. *Eur J Cancer.* 2015;51:S376.

46. Elbjeirami WM, Sughayer MA. KRAS mutations and subtyping in colorectal cancer in Jordanian patients. *Oncol Lett.* 2012;4(4):705-710.

47. Erdamar S, Ozkurt C, Dirican A. KRAS and BRAF mutation status in Turkish colorectal cancers. *Virchows Arch.* 2011;459(Suppl 1):S166.

48. Fadhil W, Ibrahim S, Ilyas M. Mutation and Expression Profile of Primary Colorectal Cancer and Related Liver Metastasis. *202nd Scientific Meeting of the Pathological Society of Great Britain & Ireland.* 2012:S6.

49. Fanetti G, Biondani P, Tessari A, et al. Pathologic response, KRAS status, and bevacizumab: The Bermuda Triangle for outcome prediction after hepatic colorectal cancer metastases (HCRM) resction. *J Clin Oncol.* 2013;31(Suppl):Abstr e14716.

50. Fanta PT, Roeland E, Shen JP, et al. Molecular predictors of treatment response in colon and gastric cancer. *Journal of Clinical Oncology.* 2012;30(4\_suppl):619-619.

51. Feigelson HS, Zeng C, Pawloski PA, et al. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. *PLoS One.* 2014;9(5):e94977.

52. Feng Q, Wei Y, Ren L, et al. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. *Oncotarget.* 2016;7(10):11380-11396.

53. Fiala O, Buchler T, Mohelnikova-Duchonova B, et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. *Tumour Biol.* 2016;37(5):6823-6830.

54. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *The Lancet Oncology.* 2010;11(1):38-47.

55. Fornaro L, Baldi GG, Masi G, et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. *Crit Rev Oncol Hematol.* 2011;78(3):243-251.

56. Francisco EB, Link JT, Ramsey M, et al. Abstract 4672: Tumor dihydropyrimide dehydrogenase (DPYD) expression is associated with survival in patients with metastatic colorectal cancer treated with gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin (IFOX). *Cancer Research.* 2010;70(8 Suppl).

57. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. *Clin Colorectal Cancer.* 2008;7(3):184-190.

58. Gajate P, Sastre J, Bando I, et al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. *Clin Colorectal Cancer.* 2012;11(4):291-296.

59. Gao J, Wang TT, Yu JW, Li YY, Shen L. Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients. *Chin J Cancer Res.* 2011;23(4):271-275.

60. Garawin T, Lowe K, Kafatos G, Murray S. The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer. *Journal of Clinical Oncology.* 2016;34(4\_suppl):598-598.

61. Garcia Foncillas J, Zazo S, Carames C, et al. Prognostic role of KRAS mutations detected by high-sensitivity taqmelt PCR assay in metastatic colorectal cancer. *Annals of Oncology.* 2012;23(Suppl 9):ix187.

62. Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, et al. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. *Tumour Biol.* 2011;32(2):417-424.

63. Garrido-Laguna I, Hong DS, Janku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. *PLoS One.* 2012;7(5):e38033.

64. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. *British journal of cancer.* 2010;103(10):1542-1547.

65. Ghidini M, Personeni N, Bozzarelli S, et al. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. *Cancer Med.* 2016;5(2):256-264.

66. Gil Ferreira C, Aran V, Zalcberg-Renault I, et al. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. *BMC Gastroenterol.* 2014;14:73.

67. Gillern SM, Chua TC, Stojadinovic A, Esquivel J. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. *Am J Clin Oncol.* 2010;33(5):456-460.

68. Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). *Ann Oncol.* 2014;25(5):1032-1038.

69. Goncalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. *BMC Cancer.* 2008;8:169.

70. Graziano F, Canestrari E, Loupakis F, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. *Pharmacogenomics J.* 2010;10(5):458-464.

71. Guedes JG, Veiga I, Rocha P, et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. *BMC Cancer.* 2013;13:169.

72. Gumus M, Dane F, Karabulut B, Uygun K, Aydin K, al. e. Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study). *Journal of Clinical Oncology.* 2015;33(15\_suppl):e14516-e14516.

73. Harbison CT, Horak CE, Ledeine JM, et al. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. *Arch Pathol Lab Med.* 2013;137(6):820-827.

74. Harle A, Filhine-Tresarrieu P, Husson M, et al. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. *Target Oncol.* 2016;11(3):363-370.

75. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol.* 2009;27(5):672-680.

76. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *The Lancet Oncology.* 2014;15(10):1065-1075.

77. Heqedus Z, Barbai T, Tatrai P, et al. 6090 POSTER KRAS Mutational Status and Anti-angiogenic Therapy in Liver Metastatic Colorectal Cancer. *European Journal of Cancer.* 2011;47:S418.

78. Hikosaka T, Yamazaki K, Hamauchi S, et al. The impact of low-frequency KRAS mutations on the efficacy of anti-EGFR antibody for patients with metastatic colorectal cancer. *Journal of Clinical Oncology.* 2014;32(3\_suppl):496-496.

79. Hong YS, Kim HJ, Park SJ, et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. *Cancer Sci.* 2013;104(4):473-480.

80. Hsieh Y-Y, Tzeng C-H, Chen M-H, Chen P-M, Wang W-S. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. *Cancer Science.* 2012;103(4):791-796.

81. Huang MY, Chen MJ, Tsai HL, et al. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. *Genet Mol Res.* 2011;10(4):3002-3012.

82. Huang CW, Tsai HL, Chen YT, et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. *BMC Cancer.* 2013;13:599.

83. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. *Oncologist.* 2009;14(1):22-28.

84. Ilie MI, Long-Mira E, Hofman V, et al. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. *Pathology.* 2014;46(4):311-315.

85. Inno A, Di Salvatore M, Cenci T, et al. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? *Clin Colorectal Cancer.* 2011;10(4):325-332.

86. Isella C, Mellano A, Galimi F, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. *Ann Surg.* 2013;257(6):1089-1095.

87. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. *Ann Surg Oncol.* 2010;17(5):1429-1434.

88. Ito Y, Yamada Y, Asada K, et al. EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. *J Cancer Res Clin Oncol.* 2013;139(8):1391-1396.

89. Iwamoto S, Hazama S, Kato T, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. *Anticancer Res.* 2014;34(4):1967-1973.

90. Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. *J BUON.* 2012;17(3):575-580.

91. Jeffers M, Cutsem EV, Sobrero A, et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. 2013.

92. Kaczirek K, Ciuleanu TE, Vrbanec D, et al. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. *Clin Colorectal Cancer.* 2015;14(2):91-98.

93. Kaneko Y, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M. Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. *Int J Clin Oncol.* 2014;19(1):113-120.

94. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. *Cancer.* 2013;119(23):4137-4144.

95. Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. *Cancer.* 2014;120(24):3965-3971.

96. Kim MJ, Lee HS, Kim JH, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. *BMC Cancer.* 2012;12:347.

97. Kim SH, Park KH, J. SS, et al. Association between CPG island methylator phenotype (CIMP) and treatment response of folfiri with cetuximab in patients with metastatic colorectal cancer (MCRC). *Annals of Oncology.* 2012;23(Suppl 11):xi41-xi42.

98. Kim HS, Heo JS, Lee J, et al. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. *BMC Cancer.* 2016;16:120.

99. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. *British journal of cancer.* 2011;104(6):1020-1026.

100. Ko YJ, Kamel-Reid S, Rowsell C, Zhang L, Yarom N, Jonker D. K-RAS and B-RAF mutations in paired primary and metastatic colorectal tumors. *Annals of Oncology.* 2011;22(Suppl 5):v26.

101. Kodaz H, Hacibekiroglu I, Erdogan B, et al. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. *Mol Clin Oncol.* 2015;3(1):179-184.

102. Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. *J Cancer Res Clin Oncol.* 2012;138(1):65-72.

103. Kohnoe S, Saeki H, Emi Y, et al. 6122 POSTER Impact of Cetuximab-based Therapy and KRas Genotypes in Japanese Patients With Chemotherapy-refractory Metastatic Colorectal Cancer. *European Journal of Cancer.* 2011;47:S429.

104. Koike J, Ushigome M, Funahashi K, et al. Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. *Hepatogastroenterology.* 2014;61(136):2222-2226.

105. Korphaisarn K, Pongpaibul A, Limwongse C, et al. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. *World J Gastroenterol.* 2015;21(3):926-934.

106. Kosmidou V, Oikonomou E, Vlassi M, et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. *Hum Mutat.* 2014;35(3):329-340.

107. Langer C, Kopit J, Awad M, et al. Analysis of K-RAS mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: results from the EPIC trial. Paper presented at: Annals of oncology2008.

108. Laszlo L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. *Magy Onkol.* 2010;54(4):383-394.

109. Lau KS, Lam KO, Choy TS, Shek WH, Chung LP, Leung TW. Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases. *Annals of Oncology.* 2015;26(suppl 9):ix46.41-ix46.

110. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol.* 2009;27(35):5924-5930.

111. Li F-H. Impact ofKRASmutation and PTEN expression on cetuximab-treated colorectal cancer. *World Journal of Gastroenterology.* 2010;16(46):5881.

112. Li YH, Wang F, Shen L, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. *Clin Cancer Res.* 2011;17(2):382-390.

113. Li Z, Liu XW, Chi ZC, Sun BS, Cheng Y, Cheng LW. Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer. *PLoS One.* 2015;10(5):e0101019.

114. Liao W, Liao Y, Zhou JX, et al. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. *Anat Rec (Hoboken).* 2010;293(9):1506-1511.

115. Licar A, Cerkovnik P, Ocvirk J, Novakovic S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. *Int J Oncol.* 2010;36(5):1137-1144.

116. Lin JK, Lin AJ, Lin CC, et al. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. *J Surg Oncol.* 2011;104(6):661-666.

117. Lin Q, Ye Q, Zhu D, et al. Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases. *PLoS One.* 2014;9(8):e105747.

118. Liou JM, Wu MS, Shun CT, et al. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. *Int J Colorectal Dis.* 2011;26(11):1387-1395.

119. Losi L, Bouzourene H, Benhattar J. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. *Oncol Rep.* 2007;17(5):1095-1099.

120. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *British journal of cancer.* 2009;101(4):715-721.

121. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol.* 2009;27(16):2622-2629.

122. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. *J Natl Cancer Inst.* 2015;107(3).

123. Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. *Clin Cancer Res.* 2008;14(23):7884-7895.

124. Ma B, Loong H, Liem GS, et al. Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer. *Journal of Clinical Oncology.* 2012;30(15\_suppl):e14085-e14085.

125. Ma BB, Chan SL, Ho WM, et al. Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. *Cancer.* 2013;119(23):4145-4153.

126. Ma BB, Mo F, Tong JH, et al. Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. *Asia Pac J Clin Oncol.* 2015;11(2):160-169.

127. Macedo MP, Lisboa BC, Begnami M, et al. Prognostic morphologic correlations of Kras gene mutations in a series of unselected colorectal carcinoma patients of a single Brazilian institution. *AMP Abstracts.* 2012;14(6):715.

128. Maestro ML, Vidaurreta M, Sanz-Casla MT, et al. Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. *Ann Surg Oncol.* 2007;14(3):1229-1236.

129. Magge D, Boone BA, Gooding WE, et al. KRAS status is a prognostic variable in cytoreductive surgery/hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. 2013:S74.

130. Mariani P, Lae M, Degeorges A, et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. *Anticancer Res.* 2010;30(10):4229-4235.

131. Martin V, Landi L, Molinari F, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. *British journal of cancer.* 2013;108(3):668-675.

132. Mekenkamp LJ, Tol J, Dijkstra JR, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. *BMC Cancer.* 2012;12:292.

133. Michl M, Heinemann V, Jung A, Engel J, Kirchner T, Neumann J. Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. *Pathol Res Pract.* 2015;211(8):601-609.

134. Miglio U, Mezzapelle R, Paganotti A, et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. *Pathol Res Pract.* 2013;209(4):233-236.

135. Miranda E, Bianchi P, Destro A, et al. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. *Cancer.* 2013;119(2):266-276.

136. Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. *Clin Colorectal Cancer.* 2011;10(4):333-339.

137. Modest DP, Stintzing S, Laubender RP, et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. *Anticancer Drugs.* 2011;22(9):913-918.

138. Modest DP, Jung A, Moosmann N, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. *Int J Cancer.* 2012;131(4):980-986.

139. Moehler M, Thomaidis T, Zeifri C, et al. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?! *J Cancer Res Clin Oncol.* 2015;141(3):515-522.

140. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. *British journal of cancer.* 2009;100(7):1087-1094.

141. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. *Clin Cancer Res.* 2011;17(14):4901-4914.

142. Montomoli J, Hamilton-Dutoit SJ, Froslev T, Taylor A, Erichsen R. Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study. *Clin Exp Gastroenterol.* 2012;5:167-171.

143. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. *J Clin Oncol.* 2011;29(8):1050-1058.

144. Morris VK, Lucas FA, Overman MJ, et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. *Ann Oncol.* 2014;25(10):2008-2014.

145. Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. *Int J Cancer.* 2013;133(1):130-141.

146. Murata A, Baba Y, Watanabe M, et al. Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. *British journal of cancer.* 2013;109(2):408-415.

147. Muro K, Yoshino T, Doi T, et al. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. *Jpn J Clin Oncol.* 2009;39(5):321-326.

148. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. *Ann Surg Oncol.* 2010;17(2):572-578.

149. Nash GM, Gimbel M, Cohen AM, et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. *Ann Surg Oncol.* 2010;17(2):416-424.

150. NIH. Study of IMC-11F8 in participants with colorectal cancer. In: NIH, ed: U.S. National Library of Medicine; 2016.

151. Netter J, Lehmann-Che J, Lambert J, et al. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. *Bull Cancer.* 2015;102(2):117-125.

152. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol Res Pract.* 2009;205(12):858-862.

153. Neumann J, Wehweck L, Maatz S, Engel J, Kirchner T, Jung A. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. *Virchows Arch.* 2013;463(4):509-523.

154. Ng K, Tabernero J, Hwang J, et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. *Clin Cancer Res.* 2013;19(14):3987-3995.

155. Ocvirk J. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. *World Journal of Gastroenterology.* 2010;16(25):3133.

156. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. *Oncogene.* 2007;26(1):158-163.

157. Ortiz C, Argiles G, Elez E, et al. Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program. *Journal of Clinical Oncology.* 2015;33(15\_suppl):3598-3598.

158. Osumi H, Shinozaki E, Osako M, et al. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. *Mol Clin Oncol.* 2015;3(5):1053-1057.

159. Osumi H, Shinozaki E, Suenaga M, et al. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. *Int J Cancer.* 2016;139(4):803-811.

160. Paez D, Pare L, Espinosa I, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? *Cancer Sci.* 2010;101(9):2048-2053.

161. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. *Am J Surg Pathol.* 2012;36(5):744-752.

162. Paliogiannis P, Cossu A, Tanda F, Palmieri G, Palomba G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. *Oncol Lett.* 2014;8(4):1422-1426.

163. Palmirotta R, Ludovici G, De Marchis ML, et al. A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. *In Vivo.* 2012;26(4):537-547.

164. Park JH, Han S-W, Oh D-Y, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. *Cancer Chemotherapy and Pharmacology.* 2011;68(4):1045-1055.

165. Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. *Cancer.* 2009;115(7):1544-1554.

166. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol.* 2010;28(31):4706-4713.

167. Peeters M, Douillard J-Y, Van Cutsem E, et al. Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab. *Journal of Clinical Oncology.* 2013;31(6):759-765.

168. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. *Ann Oncol.* 2014;25(1):107-116.

169. Pekin D, Normand C, Kotsopoulos S, et al. Abstract 4211: Detection and quantification of minoritary subclones of KRAS in metastatic colorectal cancers by digital microfluidics: therapeutic implications. *Cancer Research.* 2013;73(8 Supplement):4211-4211.

170. Pereira AAL, Rego JFM, Morris V, et al. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. *British journal of cancer.* 2014;112(3):424-428.

171. Perez-Ruiz E, Rueda A, Pereda T, et al. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. *Tumour Biol.* 2012;33(6):1829-1835.

172. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol.* 2009;20(1):84-90.

173. Phua LC, Ng HW, Yeo AH, et al. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. *Oncol Lett.* 2015;10(4):2519-2526.

174. Pichler M, Winter E, Ress AL, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. *J Clin Pathol.* 2014;67(3):198-203.

175. Pietrantonio F, Perrone F, de Braud F, et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. *Ann Oncol.* 2014;25(2):404-408.

176. Pietrantonio F, Perrone F, Cremolini C, et al. 2190 Discovery of new molecular subtypes of non-hypermutated metastatic colorectal cancer (mCRC) through a next-generation sequencing (NGS) approach. *European Journal of Cancer.* 2015;51:S396-S397.

177. Pinto P, Rocha P, Veiga I, et al. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. *Cancer Genet.* 2011;204(8):439-446.

178. Piton N, Lonchamp E, Nowak F, Sabourin JC, group K. Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* 2015;24(9):1416-1418.

179. Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. *J Clin Oncol.* 2011;29(19):2675-2682.

180. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. *The Lancet Oncology.* 2014;15(6):569-579.

181. Price TJ, Beeke C, Padbury R, et al. Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC. *Journal of Clinical Oncology.* 2014;32(3\_suppl):596-596.

182. Price TJ, Beeke C, Townsend AR, et al. BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? *Mol Diagn Ther.* 2016;20(1):75-82.

183. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. *The Lancet Oncology.* 2014;15(6):601-611.

184. Ribeiro KB, Ribeiro KB, Feres O, et al. Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma. *World J Oncol.* 2013;4(4-5):179-187.

185. Rojo F, Caldes T, Zazo S, et al. Prevalence of low-penetrance KRAS (codons 12/13 and 61) and BRAF mutations in metastatic colorectal carcinoma. *Journal of Clinical Oncology.* 2012;30(15\_suppl):e14147-e14147.

186. Rose JS, Serna DS, Martin LK, et al. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. *Cancer.* 2012;118(24):6243-6252.

187. Rosenthal MH, Kim KW, Fuchs CS, Meyerhardt JA, Ramaiya NH. CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer. *Abdom Imaging.* 2015;40(5):1170-1176.

188. Rossi L, Veltri E, Zullo A, et al. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. *Future Oncol.* 2012;8(9):1193-1197.

189. Russo AL, Borger DR, Szymonifka J, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. *Cancer.* 2014;120(10):1482-1490.

190. Ruzzo A, Graziano F, Vincenzi B, et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. *Oncologist.* 2012;17(6):823-829.

191. Saito N, Tomita S, Ichikawa K, Mitomi H, Imura J, Fujimori T. Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan. *Pathobiology.* 2014;81(3):133-137.

192. Saltz L, Badarinath S, Dakhil S, et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. *Clin Colorectal Cancer.* 2012;11(2):101-111.

193. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. *Oncologist.* 2008;13(12):1270-1275.

194. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. *British journal of cancer.* 2010;102(12):1762-1768.

195. Saridaki Z, Tzardi M, Sfakianaki M, et al. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. *PLoS One.* 2013;8(12):e84604.

196. Saridaki Z, Weidhaas JB, Lenz HJ, et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. *Clin Cancer Res.* 2014;20(17):4499-4510.

197. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res.* 2009;69(5):1851-1857.

198. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. *PLoS One.* 2009;4(10):e7287.

199. Scartozzi M, Giampieri R, Maccaroni E, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. *Ann Oncol.* 2012;23(7):1706-1712.

200. Schimanski CC, Moehler M, Gockel I, et al. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. *J Cancer Res Clin Oncol.* 2011;137(7):1139-1145.

201. Schirripa M, Cremolini C, Loupakis F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. *Int J Cancer.* 2015;136(1):83-90.

202. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol.* 2014;32(21):2240-2247.

203. Schweiger T, Hegedus B, Nikolowsky C, et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. *Ann Surg Oncol.* 2014;21(3):946-954.

204. Sebio A, Pare L, Paez D, et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. *Pharmacogenet Genomics.* 2013;23(3):142-147.

205. Selcukbiricik F, Erdamar S, Ozkurt CU, et al. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. *J BUON.* 2013;18(1):116-123.

206. Shen H, Yuan Y, Hu HG, et al. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. *World J Gastroenterol.* 2011;17(6):809-816.

207. Shen Y, Wang J, Han X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. *PLoS One.* 2013;8(12):e81628.

208. Shimomura M, Hinoi T, Kuroda S, et al. Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. *Ann Surg Oncol.* 2013;20 Suppl 3:S527-536.

209. Shoji H, Yamada Y, Taniguchi H, et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. *Cancer Sci.* 2014;105(8):1002-1007.

210. Shulman K, Barnett-Griness O, Frank M, et al. BRAF mutation, use of bevacizumab and survival of colorectal cancer. *Annals of Oncology.* 2012;23(Suppl 4):iv 102.

211. Shulman K, Barnett-Griness O, Frank M, et al. Kras Mutations in Metastatic Colorectal Cancer and the Effect of Bevacizumab. *Annals of Oncology.* 2013;24(suppl 4):iv94-iv94.

212. Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. *J BUON.* 2015;20(1):128-135.

213. Skougaard K, Johannesen HH, Nielsen D, et al. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. *Cancer Med.* 2014;3(5):1294-1301.

214. Smith BL, Breitfeld P, Cubino J, Weigman V, Richards DP, Chung KY. Abstract 5187: Feasibility study of genomic biomarker profiling for patients with metastatic colorectal cancer. *Cancer Research.* 2014;74(19 Supplement):5187-5187.

215. Smits KM, Paranjape T, Nallur S, et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. *Clin Cancer Res.* 2011;17(24):7723-7731.

216. Soeda H, Shimodaira H, Gamoh M, et al. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). *Oncology.* 2014;87(1):7-20.

217. Soeda H, Shimodaira H, Watanabe M, et al. KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. *Mol Clin Oncol.* 2014;2(3):356-362.

218. Sohal D, Rini BI, Pelley RJ, et al. Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer: Results of a prospective cohort study. *Journal of Clinical Oncology.* 2015;33(3\_suppl):593-593.

219. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. *Clin Colorectal Cancer.* 2012;11(2):143-150.

220. Sorbye H, Dragomir A, Sundstrom M, et al. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. *PLoS One.* 2015;10(6):e0131046.

221. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *British journal of cancer.* 2009;101(3):465-472.

222. Spindler KL, Pallisgaard N, Lindebjerg J, Frifeldt SK, Jakobsen A. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. *BMC Cancer.* 2011;11:107.

223. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. *Clin Cancer Res.* 2012;18(4):1177-1185.

224. Spindler KG, dePont Christensen R, Andersen RF, Pallisgaard N, Johnson A, Jakobsen A. KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study. *European Journal of Cancer.* 2012;48:146.

225. Stahler A, Heinemann V, Giessen-Jung C, et al. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). *Int J Cancer.* 2016;138(3):739-746.

226. Stintzing S, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. *Ann Oncol.* 2012;23(7):1693-1699.

227. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. *Br J Surg.* 2012;99(11):1575-1582.

228. Suenaga M, Matsusaka S, Takagi K, et al. Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients. *Journal of Clinical Oncology.* 2010;28(15\_suppl):e14107-e14107.

229. Tabernero J, Garcia-Carbonero R, Cassidy J, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. *Clin Cancer Res.* 2013;19(9):2541-2550.

230. Tabernero J, Lenz H-J, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. *The Lancet Oncology.* 2015;16(8):937-948.

231. Takahashi N, Yamada Y, Furuta K, et al. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. *British journal of cancer.* 2014;110(11):2716-2727.

232. Takahashi N, Yamada Y, Taniguchi H, et al. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer. *Arch Med Res.* 2014;45(5):366-374.

233. Tejpar S, De Roock W, Claes B, Fountzilas G, Kalogeras KT, al. e. PIK3CA, BRAF, NRAS and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with egfrtargeting monoclonal antibodies (MoAbs): Results of a European consortium. *Annals of Oncology.* 2010;21(Suppl 9):ix 6.

234. Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. *J Surg Oncol.* 2012;106(2):123-129.

235. Teufel M, Kalmus J, Rutstein M, et al. Poster 2013: Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome. *European Journal of Cancer.* 2015;51:S332.

236. Tie J, Sieber OM, Gibbs P, et al. Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation. *Journal of Clinical Oncology.* 2009;27(15\_suppl):11003-11003.

237. Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. *Int J Cancer.* 2011;128(9):2075-2084.

238. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. *Clin Cancer Res.* 2011;17(5):1122-1130.

239. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. *Eur J Cancer.* 2010;46(11):1997-2009.

240. Tommasi S, Pinto R, Petriella D, et al. Oncosuppressor methylation: a possible key role in colon metastatic progression. *J Cell Physiol.* 2011;226(7):1934-1939.

241. Tougeron D, Lecomte T, Pages JC, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. *Ann Oncol.* 2013;24(5):1267-1273.

242. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer.* 2011;117(20):4623-4632.

243. Tsimberidou AM, Leick MB, Lim J, et al. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. *Cancer Chemother Pharmacol.* 2013;71(2):389-397.

244. Tural D, Selcukbiricik F, Erdamar S, et al. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. *Hepatogastroenterology.* 2013;60(125):1035-1040.

245. Tural D, Batur S, Erdamar S, et al. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. *Tumour Biol.* 2014;35(2):1041-1049.

246. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol.* 2012;30(15):1755-1762.

247. Ulivi P, Capelli L, Valgiusti M, et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. *J Transl Med.* 2012;10:87.

248. Umeda Y, Nagasaka T, Mori Y, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. *J Hepatobiliary Pancreat Sci.* 2013;20(2):223-233.

249. Unger K, Niehammer U, Hahn A, et al. Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life. *Z Gastroenterol.* 2013;51(8):733-739.

250. Usakova V, Sevcikova K, Usak J, Bartosova Z, Mikulova M, Spanik S. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. *Neoplasma.* 2013;60(1):83-91.

251. Usakova V, Sevcikova K, Spanik S. Surgical Treatment of Metastases and Its Impact on Prognosis in Patients with Metastatic Colorectal Carcinoma: P-0244. *Annals of Oncology.* 2013;24(suppl 4):iv105-iv105.

252. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol.* 2012;30(24):2956-2962.

253. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol.* 2011;29(15):2011-2019.

254. van den Broek E, Dijkstra MJ, Krijgsman O, et al. High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. *PLoS One.* 2015;10(9):e0138141.

255. Vatandoust S, Price TJ, Padbury R, et al. Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry. *Journal of Clinical Oncology.* 2014;32(15\_suppl):e17584-e17584.

256. Vauthey J-N, Zimmitti G, Kopetz SE, et al. RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. *Annals of Surgery.* 2013;258(4):619-627.

257. Veldore VH, Rao MR, Prabhudesai SA, et al. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. *Indian J Cancer.* 2014;51(4):531-537.

258. Vermaat JS, Nijman IJ, Koudijs MJ, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. *Clin Cancer Res.* 2012;18(3):688-699.

259. Victoria I, Reig O, Gaba L, et al. RAC1b and activated Insulin-like growth factor receptor as markers of resistance to cetuximab and panitumumab in metastatic colorectal cancer. *Proffered Papers.* 2013:S567.

260. Voutsina A, Tzardi M, Kalikaki A, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. *Mod Pathol.* 2013;26(2):302-313.

261. Watanabe T, Kobunai T, Yamamoto Y, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. *Dis Colon Rectum.* 2011;54(9):1170-1178.

262. Weeraratne D, Chen A, Pennucci JJ, et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. *BMC Clin Pharmacol.* 2011;11:17.

263. Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. *J Clin Oncol.* 2012;30(13):1505-1512.

264. Wong NS, Fernando NH, Nixon AB, et al. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. *Anticancer Res.* 2011;31(1):255-261.

265. Xu JM, Liu XJ, Ge FJ, et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. *J Exp Clin Cancer Res.* 2014;33:104.

266. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. *Cancer.* 2014;120(15):2316-2324.

267. Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. *Cancer.* 2015;121(8):1195-1203.

268. Yang YH, Lin JK, Chen WS, et al. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study. *J Cancer Res Clin Oncol.* 2014;140(11):1927-1936.

269. Ye L, Zhu D, Ren L, et al. Tumor response and secondary resectability of colorectal liver metastases following cetuximab with chemotherapy: A randomized, controlled study. *Annals of Oncology.* 2012;23(suppl 11):xi37-xi38.

270. Yen LC, Uen YH, Wu DC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. *Ann Surg.* 2010;251(2):254-260.

271. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. *British journal of cancer.* 2011;104(5):856-862.

272. Zazo S, Caldes T, Perez Gonzalez N, et al. Differences in KRAS and BRAF mutation prevalence in metastatic colorectal carcinoma using high-sensitivity taqmelt vs arms-scorpion PCR assays. Paper presented at: Annals of Oncology2012.

273. Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. *Annals of Oncology.* 2010;22(1):104-109.

274. Zimmitti G, Shindoh J, Mise Y, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. *Ann Surg Oncol.* 2015;22(3):834-842.

275. Zlobec I, Molinari F, Kovac M, et al. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. *British journal of cancer.* 2010;102(1):151-161.